Loss of RACK1 promotes glutamine addiction via activating AKT/mTOR/ASCT2 axis to facilitate tumor growth in gastric cancer
ConclusionTogether, our results demonstrate that the suppressive function of RACK1 in GC is associated with ASCT2-mediated glutamine metabolism, and imply that targeting RACK1/ASCT2 axis provides potential strategies for GC treatment. (Source: Cellular Oncology)
Source: Cellular Oncology - August 14, 2023 Category: Cancer & Oncology Source Type: research
Survivin degradation by bergenin overcomes pemetrexed resistance
ConclusionsSurvivin overexpression is required for maintaining multiple malignant phenotypes of NSCLC cells. Bergenin exerts a potent antitumor effect on NSCLC via targeting survivin, rendering it a promising agent for the treatment of NSCLC. (Source: Cellular Oncology)
Source: Cellular Oncology - August 5, 2023 Category: Cancer & Oncology Source Type: research
Immunosuppressive MFAP2+ cancer associated fibroblasts conferred unfavorable prognosis and therapeutic resistance in gastric cancer
ConclusionImmunosuppressive MFAP2+ CAFs constructed an immune evasive tumor microenvironment characterized by incapacitated immune effector cells, consequently predicting inferior clinical outcomes and response on adjuvant therapy and immunotherapy in patients with GC. The potential of immunosuppressive MFAP2+ CAFs as a therapeutic target for GC deserved thoroughly exploration. (Source: Cellular Oncology)
Source: Cellular Oncology - August 4, 2023 Category: Cancer & Oncology Source Type: research
Correction to: CoQ10 reduces glioblastoma growth and infiltration through proteome remodeling and inhibition of angiogenesis and inflammation
(Source: Cellular Oncology)
Source: Cellular Oncology - August 2, 2023 Category: Cancer & Oncology Source Type: research
Crosstalk between long noncoding RNA and microRNA in Cancer
AbstractmiRNAs and lncRNAs play a central role in cancer-associated gene regulations. The dysregulated expression of lncRNAs has been reported as a hallmark of cancer progression, acting as an independent prediction marker for an individual cancer patient. The interplay of miRNA and lncRNA decides the variation of tumorigenesis that could be mediated by acting as sponges for endogenous RNAs, regulating miRNA decay, mediating intra-chromosomal interactions, and modulating epigenetic components. This paper focuses on the influence of crosstalk between lncRNA and miRNA on cancer hallmarks such as epithelial-mesenchymal tran...
Source: Cellular Oncology - July 20, 2023 Category: Cancer & Oncology Source Type: research
Epigenetic modulation of ferroptosis in cancer: Identifying epigenetic targets for novel anticancer therapy
AbstractFerroptosis is a newly recognized form of oxidative-regulated cell death resulting from iron-mediated lipid peroxidation accumulation. Radical-trapping antioxidant systems can eliminate these oxidized lipids and prevent disrupting the integrity of cell membranes. Epigenetic modifications can regulate ferroptosis by altering gene expression or cell phenotype without permanent sequence changes. These mechanisms include DNA methylation, histone modifications, RNA modifications, and noncoding RNAs. Epigenetic alterations in cancer can control the expression of ferroptosis regulators or related pathways, leading to chan...
Source: Cellular Oncology - July 12, 2023 Category: Cancer & Oncology Source Type: research
Genomic analysis and filtration of novel prognostic biomarkers based on metabolic and immune subtypes in pancreatic cancer
ConclusionThe risk score signature based on the metabolism and immune molecular subtypes can accurately predict the prognosis and guide treatments of PC, meanwhile, the metabolism-immune biomarkers may provide novel target therapy for PC (Source: Cellular Oncology)
Source: Cellular Oncology - July 11, 2023 Category: Cancer & Oncology Source Type: research
Therapeutic effects against high-grade glioblastoma mediated by engineered induced neural stem cells combined with GD2-specific CAR-NK
ConclusionsPBMC-derived iNSCsTK showed a significant tumor-tropic migration and an effective anti-tumor activity with GCVin vitro andin vivo. In addition, combined with GD2NK92, iNSCsTK therapeutic efficacy improved dramatically to prolong the tumor-bearing animal model's median survival. (Source: Cellular Oncology)
Source: Cellular Oncology - July 7, 2023 Category: Cancer & Oncology Source Type: research
Effect of infiltrating immune cells in tumor microenvironment on metastasis of hepatocellular carcinoma
AbstractHepatocellular carcinoma (HCC) is one of the most lethal and prevalent human malignancies, leading to poor prognosis due to its high recurrence and metastasis rates. In recent years it has become increasingly evident that the tumor microenvironment (TME) plays an important role in tumor progression and metastasis. Tumor microenvironment (TME) refers to the complex tissue environment of tumor occurrence and development. Here, we summarize the development of HCC and the role of cellular and non-cellular components of the TME in the metastasis HCC, with particular reference to tumor-infiltrating immune cells. We also ...
Source: Cellular Oncology - July 6, 2023 Category: Cancer & Oncology Source Type: research
Modulation of miR-146b by N6-methyladenosine modification remodels tumor-associated macrophages and enhances anti-PD-1 therapy in colorectal cancer
ConclusionsThe maturation of pri-miR-146b is m6A-dependent, and miR-146b deletion-mediated TAM differentiation promotes the development of CRC by activating the PI3K/AKT pathway, which induces upregulation of PD-L1 expression, inhibits T cell infiltration into the TME and enhances the antitumor activity of anti-PD-1 immunotherapy. The findings reveal that targeting miR-146b can serve as an adjuvant to anti-PD-1 immunotherapy.Graphical Abstract (Source: Cellular Oncology)
Source: Cellular Oncology - July 5, 2023 Category: Cancer & Oncology Source Type: research
Apo10 and TKTL1 in blood macrophages as biomarkers for differentiating lung cancer from benign lung lesions: a comparative study with conventional biomarkers
AbstractThe detection of biomarkers in blood macrophages is a new non-invasive cancer screening method, but its performance in early stage lung cancer screening remains undetermined. We evaluated the Apo10 and TKTL1 levels in blood macrophages of 156 early-stage lung cancer patients and 153 controls. APT (combination of Apo10 and TKTL1) level was significantly higher in the lung cancer group than that in the control group (P < 0.001). AUROC analysis showed that APT has high diagnostic value in differentiating early-stage lung cancer (AUC = 0.9132) and can be considered a biomarker for screening lung cancer pat...
Source: Cellular Oncology - June 28, 2023 Category: Cancer & Oncology Source Type: research
Roles of NRF2 in DNA damage repair
ConclusionNRF2 participates in a variety of DNA repair pathways and plays important roles in maintaining genome stability. NRF2 is a potential target for cancer treatment. (Source: Cellular Oncology)
Source: Cellular Oncology - June 26, 2023 Category: Cancer & Oncology Source Type: research
LncRNA CCAT2 promotes malignant progression of metastatic gastric cancer through regulating CD44 alternative splicing
ConclusionsOur findings identified a novel mechanism by which lncRNA CCAT2, as a type of protein-binding RNA,
regulates alternative splicing of CD44 and promotes GC progression. This axis may become an effective target for clinical diagnosis and treatment. (Source: Cellular Oncology)
Source: Cellular Oncology - June 24, 2023 Category: Cancer & Oncology Source Type: research
LncRNA MIR4435-2HG drives cancer progression by modulating cell cycle regulators and mTOR signaling in stroma-enriched subtypes of urothelial carcinoma of the bladder
ConclusionsOur data indicate that upregulated MIR4435-2HG expression levels are significantly correlated with a poor prognosis of UCB patients. MIR4435-2HG promotes bladder cancer progression, mediates cell cycle (de)regulation and modulates mTOR signaling. MIR4435-2HG is an oncogenic lncRNA in UCB that may serve as a diagnostic and therapeutic target. (Source: Cellular Oncology)
Source: Cellular Oncology - June 24, 2023 Category: Cancer & Oncology Source Type: research
Competition between p53 and YY1 determines PHGDH expression and malignancy in bladder cancer
ConclusionYY1 drives PHGDH expression in the context of mutant p53 and promotes bladder tumorigenesis, which preliminarily explains the relationship between high-frequency mutations of p53 and dysfunctional serine metabolism in bladder cancer. (Source: Cellular Oncology)
Source: Cellular Oncology - June 16, 2023 Category: Cancer & Oncology Source Type: research
